Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

MULTIPLE MYELOMA, GAMMOPATHIES

Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation

Leukemia volume 37, pages 2107–2114 (2023)Cite this article

Subjects

Abstract

18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET) positivity after first-line treatment with autologous stem cell transplantation (ASCT) in multiple myeloma is strongly correlated with reduced progression-free and overall survival. However, PET-positive patients who achieve PET negativity after treatment seem to have comparable outcomes to patients who were PET negative at diagnosis. Hence, giving PET-positive patients additional treatment may improve their outcome. In this phase II study, we screened first-line patients with very good partial response (VGPR) or better after ASCT with PET. PET-positive patients received four 28-day cycles of carfilzomib-lenalidomide-dexamethasone (KRd). Flow cytometry-based minimal residual disease (MRD) analysis was performed before and after treatment for correlation with PET. Overall, 159 patients were screened with PET. A total of 53 patients (33%) were PET positive and 57% of PET-positive patients were MRD negative, demonstrating that these response assessments are complementary. KRd consolidation converted 33% of PET-positive patients into PET negativity. MRD-negative patients were more likely to convert than MRD-positive patients. In summary, PET after ASCT detected residual disease in a substantial proportion of patients in VGPR or better, even in patients who were MRD negative, and KRd consolidation treatment changed PET status in 33% of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Consort diagram.
Fig. 2: PET before (upper) and after (lower) KRd treatment.
Fig. 3: Estimated mean change in global quality of life score.

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request, please contact the corresponding author by e-mail: jaknoe@ous-hf.no.

References

  1. Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103:e412–5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chakraborty R, Muchtar E, Kumar S, Buadi FK, Dingli D, Dispenzieri A, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2017;52:34–40.

    Article  CAS  PubMed  Google Scholar 

  3. Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105:e480–3.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.

    Article  CAS  PubMed  Google Scholar 

  6. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021;5:2753–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103:1047–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021;138:113–21.

    Article  CAS  PubMed  Google Scholar 

  10. Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, et al. Health-related quality-of-life results from the open-label, randomized, Phase III ASPIRE Trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6:e616–29.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34:1853–65.

    Article  CAS  PubMed  Google Scholar 

  13. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:2901–2912.

  14. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  PubMed  Google Scholar 

  15. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    Article  CAS  PubMed  Google Scholar 

  16. Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21.

    Article  CAS  PubMed  Google Scholar 

  17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

    Article  CAS  PubMed  Google Scholar 

  18. Magasi S, Mallick R, Kaiser K, Patel JD, Lad T, Johnson ML, et al. Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non–small-cell lung cancer: support for the content validity of the 4-Item Pulmonary Symptom Index. Clin Lung Cancer. 2013;14:245–53.

    Article  PubMed  Google Scholar 

  19. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. 2005;41:1135–9.

    Article  CAS  PubMed  Google Scholar 

  20. Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31–9.

    Article  CAS  PubMed  Google Scholar 

  21. Fayers PAN, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

  22. Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48:1713–21.

    Article  CAS  PubMed  Google Scholar 

  23. Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, et al. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022;6:2763–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18F-FDG–PET/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2020;39:116–25.

    Article  PubMed  Google Scholar 

  25. Zamagni E, Nanni C, Gay F, Dozza L, Rota Scalabrini D, D’Agostino M, et al. Impact of imaging FDG-PET/CT minimal residual disease assessment on outcomes and matching with bone marrow techniques in newly diagnosed transplant eligible multiple myeloma (MM) patients: results of the Phase II Randomized Forte Trial. Blood. 2020;136:27–8.

    Article  Google Scholar 

  26. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  PubMed  Google Scholar 

  27. Paiva B, Vidriales M-B, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40:2889–900.

    Article  PubMed  Google Scholar 

  29. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Alonso R, Cedena MT, Gomez-Grande A, Rios R, Moraleda JM, Cabanas V, et al. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol. 2019;94:853–61.

    Article  PubMed  Google Scholar 

  31. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–17.

    Article  PubMed  Google Scholar 

  32. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lapa C, Garcia-Velloso MJ, Luckerath K, Samnick S, Schreder M, Otero PR, et al. (11)C-Methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 2017;7:2956–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stokke C, Nørgaard JN, Feiring Phillips H, Sherwani A, Nuruddin S, Connelly J, et al. Comparison of [18F]fluciclovine and [18F]FDG PET/CT in newly diagnosed multiple myeloma patients. Mol Imaging Biol. 2022;24:842–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Acaster S, Gaugris S, Velikova G, Yong K, Lloyd AJ. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2013;21:599–607.

    Article  CAS  PubMed  Google Scholar 

  37. Ebraheem MS, Seow H, Balitsky AK, Pond GR, Wildes TM, Sivapathasundaram B, et al. Trajectory of symptoms in patients undergoing autologous stem cell transplant for multiple myeloma: a population-based cohort study of patient-reported outcomes. Clin Lymphoma Myeloma Leuk. 2021;21:e714–21.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

JNN is a PhD candidate at the University of Oslo. This work is submitted as partial fulfillment of the requirement of the PhD. KG Jebsen Center for B-cell malignancies granted funds for JNN’s PhD education. This trial was supported by research funding and drug supply from Amgen to FS. We want to thank all patients in the study and their relatives.

Author information

Authors and Affiliations

  1. Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

    Jakob Nordberg Nørgaard, Anna Lysén, Nora Remen & Fredrik Schjesvold

  2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    Jakob Nordberg Nørgaard & Mona-Elisabeth R. Revheim

  3. KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

    Jakob Nordberg Nørgaard, Anna Lysén & Fredrik Schjesvold

  4. Department of Hematology, Odense University Hospital, Odense, Denmark

    Niels Abildgaard

  5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark

    Niels Abildgaard

  6. Division of Hematology, Haukeland University Hospital, Bergen, Norway

    Galina Tsykunova

  7. Department of Hematology, Rigshospitalet, Copenhagen, Denmark

    Annette Juul Vangsted

  8. Department of Hematology, Champalimaud Centre for the Unknown, Lisboa, Portugal

    Cristina João

  9. Nova Medical School, Universidade Nova de Lisboa, Lisbon, Portugal

    Cristina João

  10. Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark

    Lene Kongsgaard Nielsen

  11. Department of Hematology, Gødstrup Hospital, Herning, Denmark

    Lene Kongsgaard Nielsen

  12. OPEN, Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark

    Lene Kongsgaard Nielsen

  13. Department of Immunology, Oslo University Hospital, Oslo, Norway

    Liv Osnes

  14. Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

    Caroline Stokke, James P. Connelly & Mona-Elisabeth R. Revheim

  15. Department of Physics, University of Oslo, Oslo, Norway

    Caroline Stokke

  16. The Intervention Centre, Oslo University Hospital, Oslo, Norway

    Mona-Elisabeth R. Revheim

Authors
  1. Jakob Nordberg Nørgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niels Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Lysén
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Galina Tsykunova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annette Juul Vangsted
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cristina João
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nora Remen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lene Kongsgaard Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Liv Osnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Caroline Stokke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. James P. Connelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mona-Elisabeth R. Revheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Fredrik Schjesvold
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Nordic Myeloma Study Group (NMSG)

  • Jakob Nordberg Nørgaard
  • , Niels Abildgaard
  • , Anna Lysén
  • , Galina Tsykunova
  • , Annette Juul Vangsted
  •  & Fredrik Schjesvold

Contributions

JNN performed research, collected data, analyzed and interpreted data, performed statistical analysis, wrote the manuscript, and approved the manuscript. NA designed research, performed research, collected data, and approved the manuscript. AL designed research, performed research, collected data, analyzed and interpreted data, and approved the manuscript. GT performed research, collected data, and approved the manuscript. AJV designed research, performed research, collected data, and approved the manuscript. CJ performed research, collected data, and approved the manuscript. NR performed research, collected data, and approved the manuscript. LKN designed the QoL substudy and collected, analyzed and interpreted data, wrote sections of the manuscript, and approved the manuscript. Henrik Eshøj designed the QoL substudy and collected, analyzed and interpreted data, and approved the manuscript. Sadly, Henrik passed away before the study was published. LO analyzed and interpreted data, wrote sections of the manuscript, and approved the manuscript. CS designed research and approved the manuscript. JPC performed research, collected data, analyzed and interpreted data, and approved the manuscript. M-ERR designed research, performed research, collected data, analyzed and interpreted data, wrote sections of the manuscript, and approved the manuscript. FS designed research, performed research, collected data, analyzed and interpreted data, performed statistical analysis, wrote the manuscript, and approved the manuscript.

Corresponding author

Correspondence to Jakob Nordberg Nørgaard.

Ethics declarations

Competing interests

JNN has received honoraria from Janssen. NA has received research grants from Janssen, Celgene, BMS, Amgen, and Takeda. GT has received consultancy/honoraria from Amgen, Janssen, Ablynx, and Sobi, as well as research funding from Amgen. FS has received honoraria from Amgen, BMS, Abbvie, Janssen, and GSK. He has received grants from Amgen and Targovax and received compensation for adbords from GSK, Takeda, BMS, Janssen, Oncopeptides, Sanofi, and XNK therapeutics. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nørgaard, J.N., Abildgaard, N., Lysén, A. et al. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation. Leukemia 37, 2107–2114 (2023). https://doi.org/10.1038/s41375-023-01998-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-01998-7

Search

Advanced search

Quick links